Annotation Detail
Information
- Associated Genes
- NRAS
- Associated Variants
-
NRAS Q61
NRAS Q61 - Associated Disease
- skin melanoma
- Source Database
- CIViC Evidence
- Description
- Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9 Patients, Gln61Arg 15 Patients). Another 13 patients had stable disease (63% disease control rate).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1226
- Gene URL
- https://civic.genome.wustl.edu/links/genes/36
- Variant URL
- https://civic.genome.wustl.edu/links/variants/94
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Skin Melanoma
- Evidence Direction
- Supports
- Drug
- Binimetinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23414587
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Binimetinib | Sensitivity | true |